Oncaspar

Servier is a global independent pharmaceutical company governed by a non-profit foundation, headquartered in Suresnes, France. The company significantly expanded its oncology presence through the 2018 acquisition of Shire's oncology business for $2.4 billion, which included the foundational leukemia treatment Oncaspar (pegaspargase). Servier's portfolio is focused on therapeutic areas including oncology, cardiovascular, metabolic, immune-inflammatory, and neurodegenerative diseases. Its oncology division is particularly robust in hematologic malignancies and solid tumors, featuring marketed products such as Oncaspar, Tibsovo, and Lonsurf. The company operates in over 150 countries and reinvests over 20% of its commercial revenue into research and development.